Which breast carcinomas need HER‐2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c‐erbB2 protein domains

Aims:  Evaluation of HER2 gene amplification in breast cancers is a compelling, routine procedure. The aim of this work was to evaluate which breast carcinomas would really benefit from HER‐2/neu gene analysis.

[1]  L. Harris,et al.  Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Dowsett,et al.  Current Perspectives on HER2 Testing: A Review of National Testing Guidelines , 2003, Modern Pathology.

[3]  O. Dietze,et al.  Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma , 2002, Laboratory Investigation.

[4]  Henry M Kuerer,et al.  Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline‐based neoadjuvant chemotherapy in patients with breast carcinoma , 2002, Cancer.

[5]  A. Au,et al.  Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma , 2002, Modern Pathology.

[6]  J. Myles,et al.  HER2/neu amplification in breast cancer: stratification by tumor type and grade. , 2002, American journal of clinical pathology.

[7]  John J Spinelli,et al.  HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.

[8]  O. Mortensen,et al.  Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK‐independent loss of epithelial morphology , 2001, International journal of cancer.

[9]  L. Holmberg,et al.  Tumour markers in breast carcinoma correlate with grade rather than with invasiveness , 2001, British Journal of Cancer.

[10]  Takashi Suzuki,et al.  Chromogenic in situ hybridization analysis of HER‐2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (Herceptin®) therapy , 2001, Pathology international.

[11]  S. Paik,et al.  HER-2 and choice of adjuvant chemotherapy in breast cancer. , 2001, Seminars in oncology.

[12]  J. Baselga,et al.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.

[13]  T. Grogan,et al.  Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  U. Lehmann,et al.  Amplification of Growth Regulatory Genes in Intraductal Breast Cancer Is Associated with Higher Nuclear Grade but Not with the Progression to Invasiveness , 2001, Laboratory Investigation.

[15]  I. Ellis,et al.  Recommendations for HER2 testing in the UK , 2000, Journal of clinical pathology.

[16]  D. Larsimont,et al.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. , 2000, The American journal of pathology.

[17]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Ridolfi,et al.  HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach , 2000, Modern Pathology.

[19]  S. Pileri,et al.  Immunohistochemical expression of internal and external ErbB‐2 domains in invasive breast cancer , 1999, Breast Cancer Research and Treatment.

[20]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Gullick,et al.  NCL‐CB11, a new monoclonal antibody recognizing the internal domain of the c‐erbB‐2 oncogene protein effective for use on formalin‐fixed, paraffin‐embedded tissue , 1990, The Journal of pathology.

[23]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[24]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[25]  A. Morey,et al.  SUGGESTIONS FOR HER‐2/neu TESTING IN BREAST CARCINOMA, BASED ON A COMPARISON OF IMMUNOHISTOCHEMISTRY AND FLUORESCENCE IN SITU HYBRIDISATION , 2001, Pathology.